Literature DB >> 23798908

Stenotrophomonas infection in a patient with glucose-6-phosphate dehydrogenase deficiency.

Aaron A Harthan1, Margaret L Heger.   

Abstract

The drug of choice for treatment of Stenotrophomonas maltophilia is sulfamethoxazole/trimethoprim, and second-line therapy usually consists of a fluoroquinolone. However, in patients with glucose-6-phosphate dehydrogenase deficiency, neither sulfamethoxazole/trimethoprim nor a fluoroquinolone is a preferred option as it may result in hemolysis. Currently, there is a paucity of data regarding treatment of S maltophilia infection in these patients. This case report presents a patient who was successfully treated with doxycycline and inhaled colistimethate.

Entities:  

Keywords:  G6PD deficiency; Stenotrophomonas; colistimethate; doxycycline

Year:  2013        PMID: 23798908      PMCID: PMC3668942          DOI: 10.5863/1551-6776-18.2.137

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  17 in total

1.  Ciprofloxacin-induced acute haemolytic anaemia in a patient with glucose-6-phosphate dehydrogenase Mediterranean deficiency: a case report.

Authors:  Stefano Sansone; Johanna Rottensteiner; Judith Stocker; Carlo Rosanelli; Christian Josef Wiedermann
Journal:  Ann Hematol       Date:  2010-02-02       Impact factor: 3.673

2.  Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin.

Authors:  G Christopher Wood; Elizabeth L Underwood; Martin A Croce; Joseph M Swanson; Timothy C Fabian
Journal:  Ann Pharmacother       Date:  2010-08-24       Impact factor: 3.154

Review 3.  Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli.

Authors:  Helio S Sader; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2005-02       Impact factor: 5.283

4.  Colistin administration to pediatric and neonatal patients.

Authors:  Elias Iosifidis; Charalampos Antachopoulos; Maria Ioannidou; Magda Mitroudi; Maria Sdougka; Vassiliki Drossou-Agakidou; Maria Tsivitanidou; Emmanuel Roilides
Journal:  Eur J Pediatr       Date:  2010-01-30       Impact factor: 3.183

5.  A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.

Authors:  Hsiu Wu; Jen-Tay Wang; Yih-Ru Shiau; Hui-Yin Wang; Tsai-Ling Yang Lauderdale; Shan-Chwen Chang
Journal:  J Microbiol Immunol Infect       Date:  2011-12-11       Impact factor: 4.399

Review 6.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 7.  Diagnosis and management of G6PD deficiency.

Authors:  Jennifer E Frank
Journal:  Am Fam Physician       Date:  2005-10-01       Impact factor: 3.292

8.  Levofloxacin-induced autoimmune hemolytic anemia.

Authors:  Young R Oh; Sian M Carr-Lopez; James M Probasco; Peter G Crawley
Journal:  Ann Pharmacother       Date:  2003 Jul-Aug       Impact factor: 3.154

Review 9.  Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature.

Authors:  Matthew E Falagas; Antonia C Kastoris; Evridiki K Vouloumanou; Petros I Rafailidis; Anastasios M Kapaskelis; George Dimopoulos
Journal:  Future Microbiol       Date:  2009-11       Impact factor: 3.165

Review 10.  Glucose-6-phosphate dehydrogenase deficiency.

Authors:  M D Cappellini; G Fiorelli
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

View more
  2 in total

1.  Infections in G6PD-Deficient Hospitalized Patients-Prevalence, Risk Factors, and Related Mortality.

Authors:  Diaa Alrahmany; Ahmed F Omar; Salima R S Al-Maqbali; Gehan Harb; Islam M Ghazi
Journal:  Antibiotics (Basel)       Date:  2022-07-12

Review 2.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.